Lymphoma News Today

Skip to content
  • Home
  • News Categories
    • Social Clips
    • Hodgkin’s Lymphoma
    • Non-Hodgkin’s Lymphoma
    • Clinical Trial
    • Leukemia & Lymphoma Society
  • About Lymphoma
    • Types Of Lymphoma
      • B-Cell Lymphoma
      • Benign Lymphoma
      • Burkitt’s Lymphoma
      • Cutaneous Lymphoma
      • Follicular Lymphoma
      • Indolent Lymphoma
      • Intestinal Lymphoma
      • Low Grade Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
    • Lymphoma Symptoms
      • Lymphedema
    • Signs Of Lymphoma
    • Lymphoma Diagnosis
    • Lymphoma Prognosis
  • Treatments
    • Approved Treatments
      • CAR T-cell Therapy
        • Kymriah (Tisagenlecleucel)
        • Yescarta (KTE-C19)
      • Adcetris (Brentuximab Vedotin)
      • Aliqopa (Copanlisib)
      • Arzerra (Ofatumumab)
      • Beleodaq (Belinostat)
      • Bendamustine in Lymphomas
      • Besponsa (Inotuzumab Ozogamicin)
      • Calquence (Acalabrutinib)
      • CPX-351
      • Gazyva (Obinutuzumab)
      • Imbruvica (Ibrutinib)
      • Keytruda for Classical Hodgkin Lymphoma (cHL)
      • Rituxan (Rituximab)
      • Rituxan Hycela
      • Revlimid (lenalidomide)
      • Velcade (bortezomib)
      • Venclexta (Venetoclax)
      • Zydelig (Idelalisib)
    • Experimental Treatments
      • ABP798 for Non-Hodgkin’s Lymphoma
      • ADCT-301 in Lymphomas
      • AFM11 for B-Cell Lymphoma
      • AFM13 for Hodgkin’s Lymphoma
      • ALT-803 for Non-Hodgkin Lymphomas
      • Betalutin
      • CMD-003 for Hodgkin’s and non-Hodgkin’s Lymphomas
      • CX-072
      • CPI-818
      • DI-Leu16-IL2
      • Duvelisib
      • GWN323
      • IGN002 for Non-Hodgkin’s Lymphoma
      • Imfinzi (Durvalumab)
      • JCAR017 for B-Cell Non-Hodgkin’s Lymphoma (NHL)
      • JCAR018
      • KTE-X19
      • Mogamulizumab
      • NM-IL-12
      • Oncoquest-L for Follicular Lymphoma
      • OXS-1550
      • PDR001 in Lymphoma
      • Resimmune
      • RG7741 (GDC-0575)
      • Tecentriq (Atezolizumab)
      • TG-1101 (Ublituximab)
      • TGR-1202 (Umbralisib)
      • Xalkori (Crizotinib)
  • Columns
    • Overcoming Adversity
    • Things That Give Me Hope
    • Life After Lymphoma: A Young Warrior’s Guide to Recovery
  • Information About COVID-19

Faster Assay To Screen And Profile Different Subtypes of B Cell Lymphoma Developed

May 7, 2015May 7, 2015
Ines Martins, PhDby Ines Martins, PhD

In News.

Faster Assay To Screen And Profile Different Subtypes of B Cell Lymphoma Developed

Click here to subscribe to the Lymphoma News Today Newsletter!

0
(0)

Distinguishing between the major types of lymphomas is important in order for physicians to accurately match a targeted therapy for adequate treatment. With more and more targeted therapies being launched, it becomes very important to differentiate between the major types of Diffuse Large B Cell Lymphomas (DLBCL) — namely, Germinal Centre B Cell like (GCB) and Activated B Cell like (ABC), as their management strategies are different and affect treatment outcomes.

The main challenge faced by scientists while diagnosing cases of B cell lymphoma is its morphological similarity, which makes the application of targeted therapy difficult. The gold standard for distinguishing between different kinds of lymphomas is array-based Gene Expression Profiling (GEP), followed by Immunohistochemistry (IHC), both of which have their shortcomings in terms of efficacy and reliability.

A group of researchers led by lead investigator Philippe Ruminy, PhD, of the Centre Henri Becquerel, Institute for Research and Innovation in Biomedicine, University of Rouen (France), examined 259 lymph node biopsies from patients including 195 patients from the Centre Henri Becquerel and 64 from an external group (the Lymphoma Study Association) with different forms of DLBCL. The team used a technique called reverse transcriptase multiplex ligation-dependent probe amplification (RT-MLPA) assay to distinguish between different lymphoma subtypes. This method proved effective in identifying and distinguishing tumor subtypes, up to 90% and 93% in two sets of tests with randomly selected samples.

In addition, the assay was useful in detecting subtypes from low-concentration samples like frozen and archived formalin-fixed, paraffin-embedded (FFPE) tissues. When tested among 28 such samples, it gave accurate results in 89.3% of cases. According to Dr. Rumini, “Because RT-MLPA requires only short cDNA fragments for the correct binding and ligation of the gene-specific oligonucleotide probes, it is less affected by the use of low RNA concentrations and RNA degradation. It could thus be used for the retrospective analysis of archival collections and for the inclusion of patients in prospective clinical trials, because only a few institutions routinely collect frozen biopsy material.”

RT-MLPA was also beneficial in determining the prognostic value of patients with different forms of the tumor. For instance, while evaluating the chances of survival of 135 patients diagnosed and treated between 2001 and 2011, patients with the ABC subtype were found to have a significantly worse progression free survival and overall survival when compared to their GCB counterparts. Gene expression of several genes identified through this assay (high LMO2, high BCL6, and low TNFRSF13B expression) also proved helpful to detect the exact genotype of this condition.

Dr. Ruminy concluded, saying, “The robust and cost-effective RT-MLPA assay can yield results within one day and requires reagents costing less than $5 per sample. Since RT-MLPA utilizes materials and equipment that are standard in many laboratories, the process can easily be implemented for routine use.”

  • Author Details
Ines Martins, PhD
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Ines Martins, PhD
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • ATG-019 Phase 1 trial
  • ME-401, FDA fast track
  • Tafasitamab combo, lymphoma
  • blood biomarkers
Print Friendly, PDF & EmailPrint This Page

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Tagged Activated B Cell like (ABC), B cell lymphoma, Gene Expression Profiling, Germinal Centre B Cell like (GCB), RT-MLPA.

Post navigation

Previous: Hodgkin Lymphoma-Associated Therapy Increases Risk of Cardiovascular Conditions
antibodies and hepatitis cNext:Hodgkin Lymphoma Patients Adequately Treated With Chemotherapy Without Radiotherapy

Recent Posts

  • farewell, honesty, impact, sometimes, superheroes

    A Farewell Note to My Beloved Readers

    February 26, 2021

  • farewell, honesty, impact, sometimes, superheroes

    A Light-giver Shares a Lesson in Emotional Honesty

    February 15, 2021

  • farewell, honesty, impact, sometimes, superheroes

    Embarking on a New Chapter While Cherishing the Value of Community

    February 1, 2021

Featured Posts

FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma

March 19, 2020

Umbralisib orphan drug

The Paradox of Healing

March 9, 2020

grateful, happiness, coronavirus, beauty
Visit Lymphoma News Today's profile on Pinterest.

Lymphoma News Today

BioNews Services, LLC
3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
  • About Us
  • Our Team
  • Our Guiding Ethics
  • Contact Us
  • Terms of Service
  • Privacy Policy
  • Disable Notifications

Disclaimer:

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2022 Copyright 2015 © All rights reserved